Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib) – Phase 1/2…
Originalartikel lesen: …brigatinib) – Business Wire China
